Go offline with the Player FM app!
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
Manage episode 412050269 series 1021077
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers.
These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at the University of Texas Southwestern Medical Center.
After McArthur’s talk in Italy, she shared the details with Peter Goodwin, OncTimesTalk correspondent.
136 episodes
Manage episode 412050269 series 1021077
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers.
These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at the University of Texas Southwestern Medical Center.
After McArthur’s talk in Italy, she shared the details with Peter Goodwin, OncTimesTalk correspondent.
136 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.